Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
136 studies found for:    "acute promyelocytic leukemia"
Show Display Options
Rank Status Study
21 Recruiting Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: ATRA+arsenic;   Drug: ATRA+chemo
22 Active, not recruiting Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia
Conditions: Leukemia;   Acute Lymphoblastic Leukemia;   Acute Promyelocytic Leukemia
Intervention: Other: laboratory biomarker analysis
23 Terminated ASCT for Relapsed APL After Molecular Remission
Conditions: Acute Promyelocytic Leukemia;   Relapse
Intervention: Procedure: autologous hematopoietic cell transplantation
24 Completed Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: Tamibarotene
25 Completed High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Acute Promyelocytic Leukemia (M3);   Adult Erythroleukemia (M6a);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pure Erythroid Leukemia (M6b);   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Burkitt Lymphoma;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Acute Promyelocytic Leukemia (M3);   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   De Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-Cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Procedure: allogeneic bone marrow transplantation;   Drug: methylprednisolone;   Drug: methotrexate;   Drug: cyclosporine
26 Active, not recruiting A Safety Study of SGN-CD33A in AML Patients
Conditions: Acute Myelogenous Leukemia;   Acute Myeloid Leukemia;   Acute Promyelocytic Leukemia
Interventions: Drug: HMA;   Drug: SGN-CD33A
27 Unknown  Acute Promyelocytic Leukemia 2006 (APL)
Condition: Leukemia, Promyelocytic, Acute
Interventions: Procedure: Arsenic trioxide;   Procedure: ATRA
28 Unknown  Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Myeloproliferative Disorders;   Acute Lymphocytic Leukemia;   Acute Promyelocytic Leukemia;   Acute Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Juvenile Myelomonocytic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide
29 Recruiting National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
Conditions: Newly-diagnosed APL (de Novo or Therapy-related);   Relapsed APL
Intervention: Other: observational
30 Completed Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
Condition: Leukemia
Intervention: Drug: arsenic trioxide
31 Completed Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin
32 Completed Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
Condition: Leukemia
Interventions: Biological: lintuzumab;   Drug: cytarabine;   Drug: idarubicin
33 Withdrawn Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: homoharringtonine;   Procedure: chemotherapy
34 Completed Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Biological: filgrastim;   Biological: lintuzumab;   Drug: arsenic trioxide;   Drug: idarubicin;   Drug: tretinoin
35 Recruiting Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin
Condition: Leukemia
Interventions: Drug: ATRA;   Drug: ATO;   Drug: GO (Gemtuzumab ozogamicin);   Drug: Methylprednisolone
36 Unknown  AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
Condition: Leukemia, Promyelocytic, Acute
Interventions: Drug: all-trans retinoid acid;   Drug: idarubicin;   Drug: mitoxantrone;   Drug: daunorubicin;   Drug: cytarabine
37 Active, not recruiting Phase III Trial in Acute Promyelocytic Leukemia Patients
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: all-trans retinoic acid;   Drug: all-trans retinoic acid (ATRA)
38 Terminated
Has Results
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: idarubicin;   Drug: tretinoin
39 Active, not recruiting S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: gemtuzumab ozogamicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin
40 Unknown  Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: etoposide;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: thioguanine;   Drug: tretinoin;   Procedure: allogeneic bone marrow transplantation;   Procedure: autologous bone marrow transplantation;   Radiation: radiation therapy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years